Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (NYSE: IQV) is frequently in the news as a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. News coverage about IQVIA highlights how the company combines high-quality health data, Healthcare-grade AI®, advanced analytics and technology to support clinical development and commercial decision-making.
On this page, readers can follow IQVIA news related to clinical research initiatives, technology launches and strategic partnerships. Recent announcements include a strategic collaboration with Amazon Web Services, under which AWS has been named IQVIA’s Preferred Agentic Cloud Provider to power a next-generation AI platform. Other news items describe the launch of IQVIA’s Clinical Trial Financial Suite, an AI-enabled platform for managing financial aspects of clinical trials, and partnerships with organizations such as Veeva Systems.
IQVIA news also covers topics such as quarterly financial results, leadership and board changes, awards for site relationships in clinical research and the expansion of clinical research networks. For example, the company reports on its Research & Development Solutions bookings and backlog, as well as its recognition with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication.
Investors, researchers and industry professionals can use this news feed to monitor developments in IQVIA’s clinical research services, healthcare analytics capabilities, AI initiatives and collaborations across the life sciences ecosystem. Regularly reviewing IQVIA news can provide insight into how the company is applying data, analytics and technology to support the development and commercialization of medical treatments.
IQVIA (NYSE:IQV) on March 16, 2026 launched IQVIA.ai, a unified agentic AI platform built with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo and LangChain to accelerate clinical, commercial and real-world workflows while meeting healthcare regulatory, privacy and quality standards.
IQVIA reported a collaboration with NVIDIA of more than one year, filed over 100 AI-related patents, deployed more than 150 intelligent agents, and said 19 of the top 20 pharmaceutical companies have begun using IQVIA agents; expanded capabilities expected in Q4.
IQVIA (NYSE:IQV) announced that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026 at 9:30 a.m. ET.
A live audio webcast will be available on the company investor relations website, with a replay posted later the same day.
IQVIA (NYSE:IQV) announced that chairman and CEO Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 9:20 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay available later that day.
IQVIA (NYSE: IQV) published its 2025 Sustainability Report, highlighting progress across People, Public and Planet pillars. Key metrics include >230,000 AI learning engagements, >2,000 leadership program participants, activation of Brazil and Argentina sites enrolling 5,700 patients toward a 47,000 global trial target, and 56 Prime Sites.
Environmental actions include 100% My Green Lab certification, test kits using ≥98% recycled materials and a 70% cut in cold‑chain packaging emissions.
IQVIA (NYSE: IQV) announced it will acquire certain discovery services assets from Charles River Laboratories, adding five sites that offer in vitro New Approach Methodologies (NAMs) and a small-molecule AI platform.
The assets include >20 years of curated scientific data, have supported 100+ molecules entering clinical trials and several approved drugs. The deal expands IQVIA Laboratories into an end-to-end drug discovery platform. The transaction is expected to close in the second quarter, 2026.
IQVIA (NYSE:IQV) said CFO Ron Bruehlman and SVP FP&A and incoming CFO Mike Fedock will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026 at 11:00 a.m. ET.
A live audio webcast and same‑day replay will be available on IQVIA's Investor Relations website.
IQVIA (NYSE:IQV) and Duke Clinical Research Institute (DCRI) announced a strategic collaboration on February 10, 2026 to accelerate clinical research in obesity and related cardiometabolic conditions. The partnership combines IQVIA operational scale and real-world data with DCRI academic trial design and execution.
Key capabilities include access to patients across 56 countries and >3,000 sites, IQVIA’s experience with >120 obesity trials and >90,000 patients enrolled, and combined analytics, biostatistics and AI-enabled trial execution to support faster, more representative studies and regulatory submissions.
IQVIA (NYSE:IQV) reported fourth-quarter 2025 revenue of $4,364M and full-year revenue of $16,310M, with fourth-quarter GAAP net income of $514M and full-year GAAP net income of $1,360M. Adjusted diluted EPS was $3.42 Q4 and $11.92 full-year. R&DS backlog totaled $32.7B and quarterly R&DS bookings exceeded $2.7B (book-to-bill 1.18x). Operating cash flow was $735M Q4 and $2,654M full-year; free cash flow was $561M Q4 and $2,051M full-year. Full-year 2026 guidance: revenue $17,150–17,350M, Adjusted EBITDA $3,975–4,025M, Adjusted diluted EPS $12.55–12.85.
IQVIA (NYSE:IQV) announced a strategic, long-term collaboration with Boehringer Ingelheim to use IQVIA’s Data-as-a-Service (DaaS+) platform as the accelerator for global commercial data harmonization and transformation.
The deal targets harmonized market, brand and franchise reporting across 59 countries, cloud-native ingestion, global product mastering, and aims to support upcoming launches, improve market performance and enable AI-powered analytics.
IQVIA (NYSE:IQV) was named No. 1 in the Health Care: Pharmacy and Other Services category on the 2026 Fortune® World’s Most Admired Companies™ list.
This marks IQVIA's fifth consecutive year at No. 1 in its sector and its ninth consecutive year on the list. IQVIA ranked first in seven of nine evaluated attributes, including innovation, people management, use of corporate assets, financial soundness, long-term investment value, quality of products/services, and global competitiveness. Fortune and Korn Ferry analyzed 685 companies and surveyed more than 3,000 executives for the annual reputational ranking.